TY - JOUR
T1 - Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry
AU - Lawrence, Neil
AU - Bacila, Irina
AU - Dawson, Jeremy
AU - Bryce, Jillian
AU - Ali, Salma R.
AU - van den Akker, Erica L. T.
AU - Bachega, T. nia A. S. S.
AU - Baronio, Federico
AU - Birkebæk, Niels H.
AU - Bonfig, Walter
AU - van der Grinten, Hedi C.
AU - Costa, Eduardo C.
AU - de Vries, Liat
AU - Elsedfy, Heba
AU - Güven, Ayla
AU - Hannema, Sabine
AU - Iotova, Violeta
AU - van der Kamp, Hetty J.
AU - León, Maria C.
AU - Lichiardopol, Corina R.
AU - Milenkovic, Tatjana
AU - Neumann, Uta
AU - Nordenström, Ana
AU - Poyrazoğlu, Şukran
AU - Probst-Scheidegger, Ursina
AU - de Sanctis, Luisa
AU - Tadokoro-Cuccaro, Rieko
AU - Thankamony, Ajay
AU - Vieites, Ana
AU - Yavaş, Zehra
AU - Faisal Ahmed, Syed
AU - Krone, Nils
N1 - Funding Information: This study would not be possible without the patients and the parents of the children with CAH whose data have been included in the I‐CAH Registry. This project has received support from the I‐CAH Registry project that receives unrestricted education grants from Diurnal Ltd and Neurocrine Biosciences. The initial development of the Registry was supported by the Medical Research Council (G1100236), the Seventh European Union Framework Program (201444) and the European Society for Paediatric Endocrinology Research Unit. NRL is funded by an NIHR Academic Clinical Fellowship. SRA is supported by the Gardiner Lectureship at the University of Glasgow. This study was funded by an award to NPK from the DFG, German Research Foundation (KR3363/3‐1). Publisher Copyright: © 2022 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
PY - 2022/11
Y1 - 2022/11
N2 - Objective: Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4). Design: Retrospective cohort study using real-world data to evaluate 17OHP and D4 in relation to hydrocortisone (HC) dose in CAH patients treated in 14 countries. Patients: Pseudonymized data from children with 21-hydroxylase deficiency (21OHD) recorded in the International CAH Registry. Measurements: Assessments between January 2000 and October 2020 in patients prescribed HC were reviewed to summarise biomarkers 17OHP and D4 and HC dose. Longitudinal assessment of measures was carried out using linear mixed-effects models (LMEM). Results: Cohort of 345 patients, 52.2% female, median age 4.3 years (interquartile range: 3.1–9.2) were taking a median 11.3 mg/m2/day (8.6–14.4) of HC. Median 17OHP was 35.7 nmol/l (3.0–104.0). Median D4 under 12 years was 0 nmol/L (0–2.0) and above 12 years was 10.5 nmol/L (3.9–21.0). There were significant differences in biomarker values between centres (p < 0.05). Correlation between D4 and 17OHP was good in multiple regression with age (p < 0.001, R2 = 0.29). In longitudinal assessment, 17OHP levels did not change with age, whereas D4 levels increased with age (p < 0.001, R2 = 0.08). Neither biomarker varied directly with dose or weight (p > 0.05). Multivariate LMEM showed HC dose decreasing by 1.0 mg/m2/day for every 1 point increase in weight standard deviation score. Discussion: Registry data show large variability in 17OHP and D4 between centres. 17OHP correlates with D4 well when accounting for age. Prescribed HC dose per body surface area decreased with weight gain.
AB - Objective: Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4). Design: Retrospective cohort study using real-world data to evaluate 17OHP and D4 in relation to hydrocortisone (HC) dose in CAH patients treated in 14 countries. Patients: Pseudonymized data from children with 21-hydroxylase deficiency (21OHD) recorded in the International CAH Registry. Measurements: Assessments between January 2000 and October 2020 in patients prescribed HC were reviewed to summarise biomarkers 17OHP and D4 and HC dose. Longitudinal assessment of measures was carried out using linear mixed-effects models (LMEM). Results: Cohort of 345 patients, 52.2% female, median age 4.3 years (interquartile range: 3.1–9.2) were taking a median 11.3 mg/m2/day (8.6–14.4) of HC. Median 17OHP was 35.7 nmol/l (3.0–104.0). Median D4 under 12 years was 0 nmol/L (0–2.0) and above 12 years was 10.5 nmol/L (3.9–21.0). There were significant differences in biomarker values between centres (p < 0.05). Correlation between D4 and 17OHP was good in multiple regression with age (p < 0.001, R2 = 0.29). In longitudinal assessment, 17OHP levels did not change with age, whereas D4 levels increased with age (p < 0.001, R2 = 0.08). Neither biomarker varied directly with dose or weight (p > 0.05). Multivariate LMEM showed HC dose decreasing by 1.0 mg/m2/day for every 1 point increase in weight standard deviation score. Discussion: Registry data show large variability in 17OHP and D4 between centres. 17OHP correlates with D4 well when accounting for age. Prescribed HC dose per body surface area decreased with weight gain.
KW - biomarkers
KW - congenital adrenal hyperplasia
KW - hydrocortisone
KW - linear mixed-effects models
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85133935987&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/35781728
U2 - https://doi.org/10.1111/cen.14796
DO - https://doi.org/10.1111/cen.14796
M3 - Article
C2 - 35781728
SN - 0300-0664
VL - 97
SP - 551
EP - 561
JO - Clinical endocrinology
JF - Clinical endocrinology
IS - 5
ER -